Press coverage about Atrion Corporation (NASDAQ:ATRI) has trended positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Atrion Corporation earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.6764185121067 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, BidaskClub upgraded shares of Atrion Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 29th.
Atrion Corporation (NASDAQ ATRI) traded up 2.37% during mid-day trading on Monday, hitting $680.00. 8,761 shares of the stock traded hands. The firm has a market capitalization of $1.26 billion, a P/E ratio of 38.10 and a beta of 0.91. The company has a 50-day moving average of $631.23 and a 200 day moving average of $559.66. Atrion Corporation has a 1-year low of $393.95 and a 1-year high of $691.95.
Atrion Corporation (NASDAQ:ATRI) last announced its quarterly earnings results on Tuesday, August 8th. The medical instruments supplier reported $5.40 EPS for the quarter. Atrion Corporation had a return on equity of 18.67% and a net margin of 22.75%. The company had revenue of $36.16 million during the quarter. On average, equities research analysts anticipate that Atrion Corporation will post $9.90 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 15th will be paid a $1.20 dividend. This is a positive change from Atrion Corporation’s previous quarterly dividend of $1.05. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $4.80 dividend on an annualized basis and a yield of 0.72%. Atrion Corporation’s dividend payout ratio (DPR) is presently 23.52%.
In related news, Chairman Emile A. Battat sold 1,408 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $652.91, for a total value of $919,297.28. Following the completion of the sale, the chairman now owns 148,881 shares of the company’s stock, valued at $97,205,893.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 24.23% of the company’s stock.
WARNING: “Atrion Corporation (ATRI) Earns News Sentiment Score of 0.26” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/09/11/atrion-corporation-atri-earns-news-sentiment-score-of-0-26.html.
About Atrion Corporation
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.